Astrazeneca plc recently provided details on the discovery of the potent, direct and selective NLPR3 inflammasome inhibitor AZD-4144 for the treatment of inflammatory diseases.
Researchers from Chroma Medicine Inc. presented preclinical data for the novel PCSK9-targeted epigenetic editor (PCSK9-EE) being developed as cardiovascular therapy for the reduction of low-density lipoprotein cholesterol.
Researchers from Corteria Pharmaceuticals SAS and Université Paris-Saclay recently presented the preclinical results on a long-acting corticotropin-releasing factor CRF2 receptor agonist, COR-1389.
Essential branched-chain amino acids (BCAA) such as leucine, isoleucine or valine, cannot be synthesized by mammals, making them an obligate part of the diet.
Researchers from Astrazeneca plc presented the structure and preclinical characterization of a novel PCSK9 inhibitor, AZD-0780, being developed for the treatment of cardiovascular disease. A new potentially druggable functional binding pocket was identified on the PCSK9 C-terminal domain (CTD), and multiple fragment screens generated a single CTD-binding hit.
Researchers from the National University of Singapore and affiliated organizations presented data from a study that investigated the potential of targeting chondroitin sulfate (CS) synthesis as a therapeutic strategy for ameliorating hyperplastic arterial remodeling.
The valosin-containing protein (VCP) modulator KUS-121 from Kyoto University is in phase II development as an intravitreal treatment for nonarteritic central retinal artery occlusion, but its efficacy in atherosclerosis is unknown.
Repolarization abbreviation with the antiarrhythmic drug mexiletine has been found to normalize the QTc interval and reduce the rate of events in long QT syndrome type 3 (LQT3), but it is only partially efficacious in other malignant forms, including LQT2 and LQT8. There are compounds that have not been tested, such as hERG channel agonists, which are capable of shortening repolarization. The potent hERG agonist ICA-105574 was thus tested in a clinically relevant porcine model of LQT8.
At the recent European Society of Cardiology meeting, Anacardio AB and Helsinn Healthcare SA presented data on their oral small-molecule ghrelin receptor agonist and first-in-class calcium sensitizing inotrope, AC-01, in preclinical models of heart failure.
RSS
